Translate Bio (TBIO) Prices 12.507M Share Common Offering at $22/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
SunTrust Starts Translate Bio (TBIO) at Buy
June 26, 2020 5:30 AM UTCSunTrust analyst Joon Lee initiates coverage on Translate Bio (NASDAQ: TBIO) with a Buy rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Translate Bio click here. For more ratings news on Translate Bio click here.
Shares of Translate Bio closed at $24.67 yesterday.
... MoreTranslate Bio (TBIO) PT Raised to $35 at Citi
June 26, 2020 5:23 AM UTCCiti analyst Yigal Nochomovitz raised the price target on Translate Bio (NASDAQ: TBIO) to $35.00 (from $17.00) while maintaining a Buy rating.... More
Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources
June 25, 2020 10:23 AM UTCBy Matthias Blamont
PARIS (Reuters) - Sanofi is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs.
Management will meet staff representatives on Friday and Monday next week to outline a restructuring plan, five sources familiar with the matter told Reuters. They declined to be identified as the plan is still confidential.
The reorganisation could involve several European countries and possibly others outside the region, as... More
Pre-Open Stock Movers 06/25: (EKSO) (GNC) (ALLY) Higher; (MGTA) (KBH) (XERS) Lower (more...)
June 25, 2020 9:26 AM UTCPre-Open Stock Movers
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) 79% HIGHER; received 501(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNRTM robotic exoskeleton for use with patients with acquired brain injury (ABI). EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use with ABI, significantly expanding the devices indication to a broader group of patients.
GNC Holdings, Inc. (NYSE: GNC) 36.3% HIGHER; bankrupt stock sees upside
Magenta Therapeutics, Inc.... More
After-Hours Movers 06/24: (ALLY) (BDN) (RPAI) Higher; (XERS) (QURE) (NK) Lower (more...)
June 24, 2020 5:46 PM UTCAfter-Hours Movers
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) 14.9% LOWER; announced that it has commenced concurrent underwritten public offerings of $20,000,000 in shares of its common stock (the Shares) and $60,000,000 aggregate principal amount of convertible senior notes due 2025 (the Notes).
uniQure N.V. (NASDAQ: QURE) 12.8% LOWER; announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQures investigational gene therapy for patients with hemophilia B. Etranacogene... More
Translate Bio (TBIO) Announces $125 Million Proposed Public Offering of Common Stock
June 24, 2020 4:19 PM UTCTranslate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has commenced an underwritten public offering of $125.0 million of its common stock. In addition, Shire Human Genetic Therapies, Inc. (Shire), a... More
